-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SNV-0 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SNV-0 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SNV-0 in Solid Tumor Drug Details: SVF-CAL1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AL-8326 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AL-8326 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AL-8326 in Small-Cell Lung Cancer Drug Details: AL-8326 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Retifanlimab in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Retifanlimab in Sarcomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Retifanlimab in Sarcomas Drug Details: Retifanlimab (Zynyz) is a humanized IgG4 kappa...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMC-2015 in Osteonecrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMC-2015 in Osteonecrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IMC-2015 in OsteonecrosisDrug Details:IMC-2015 is under development for the treatment of avascular necrosis. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MGS-2525 in Chronic Obstructive Pulmonary Disease (COPD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MGS-2525 in Chronic Obstructive Pulmonary Disease (COPD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MGS-2525 in Chronic Obstructive Pulmonary Disease (COPD) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TP-3654 in Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TP-3654 in Post-Polycythemia Vera Myelofibrosis (PPV-MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TP-3654 in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drug Details:TP-3654 (SGI-9481) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PM-54 in Ewing Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PM-54 in Ewing Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PM-54 in Ewing Sarcoma Drug Details: PM-54 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talazoparib in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talazoparib in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talazoparib in Adenocarcinoma Of The Gastroesophageal Junction Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Neuroendocrine Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Neuroendocrine Tumors report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Neuroendocrine Tumors Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio) a...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SNV-0
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SNV-0 Drug Details SVF-CAL1 is under development for the treatment of solid tumor. The...